GYRE

BEARISH

$7.39 Live

Gyre Therapeutics, Inc. · NASDAQ

Target $18.67 (+152.6%)

$6.57 52W Range $11.78

GYRE Gyre Therapeutics, Inc. - Fundamental Analysis

BEARISH

Console Chart News

GYRE Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$7.39

Analyst Target

$18.67

+152.6% Upside

52W High

$11.78

52W Low

$6.57

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 11, 2026

Market cap

$711.9M

P/E

369.5

ROE

8.2%

Profit margin

4.3%

Debt/Equity

0.01

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

GYRE exhibits significant financial fragility and valuation misalignment, evidenced by a weak Piotroski F-Score of 3/9 and a Graham Number of $0.72, which is a fraction of the current $7.39 price. While the company maintains a strong liquidity position with a Current Ratio of 5.60 and negligible debt, its valuation is extreme with a P/E ratio of 369.50. The disconnect between the intrinsic value ($0.14) and the market price suggests the stock is trading on speculative future expectations rather than current fundamentals. Technical trends are entirely bearish (0/100), and earnings consistency is poor, with only one beat in the last four quarters.

Key Strengths

Exceptionally low Debt/Equity ratio (0.01)

Strong short-term liquidity (Current Ratio 5.60)

High Gross Margin (95.36%) indicating strong product pricing power

Consistent revenue growth (33.4% YoY)

Significant upside gap to analyst target price ($18.67)

Key Risks

Extreme valuation premium (P/E 369.50 vs Sector Avg 43.24)

Weak operational health as indicated by Piotroski F-Score (3/9)

Severe divergence between current price and Graham/Intrinsic value

Poor earnings track record with a recent Q/Q EPS collapse of -166.7%

Bearish technical momentum and negative 1-month price action

AI Fair Value Estimate

Based on comprehensive analysis

$1.25

-83.1% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Overvaluation

Key drivers: Extreme P/E ratio, Low Piotroski F-Score, Strong balance sheet liquidity, Bearish technicals

Confidence

90%

Value

10/100

Ref P/E, PEG, Graham Number

Positives

No standout positives identified.

Watchpoints

P/E of 369.50
Price/Book of 6.37
Current price is >10x the Graham Number

Future

55/100

Ref Growth rates

Positives

33.4% Revenue Growth
High Analyst Target Price

Watchpoints

Volatile EPS
Poor earnings surprise history

Past

30/100

Ref Historical trends

Positives

3Y Change +134.6%

Watchpoints

5Y Change -40%
Recent 1M decline of 11.3%

Health

40/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Debt/Equity 0.01
Current Ratio 5.60

Watchpoints

Piotroski F-Score 3/9

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$7.39

Analyst Target

$18.67

Upside/Downside

+152.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for GYRE and closest competitors.

Updated 2026-04-10

Company	5Y	3Y	1Y	6M	1M	1W
GYRE Gyre Therapeutics, Inc. Primary	-40.0%	+134.6%	+1.4%	-7.2%	-11.3%	+3.8%
ETON Eton Pharmaceuticals, Inc. Peer	+251.9%	+598.3%	+130.1%	+26.1%	+58.0%	+4.1%
BBNX Beta Bionics, Inc. Peer	-32.5%	-32.5%	-32.5%	+7.5%	-48.7%	-13.7%
GDRX GoodRx Holdings, Inc. Peer	-94.7%	-62.4%	-53.9%	-53.5%	-10.0%	+5.4%
BGM BGM Group Ltd. Peer	-90.8%	-38.2%	-66.0%	-64.4%	-12.5%	0.0%

GYR

Gyre Therapeutics, Inc.

Primary

-40.0%

+134.6%

+1.4%

-7.2%

-11.3%

+3.8%

ETO

Eton Pharmaceuticals, Inc.

Peer

+251.9%

+598.3%

+130.1%

+26.1%

+58.0%

+4.1%

BBN

Beta Bionics, Inc.

Peer

-32.5%

+7.5%

-48.7%

-13.7%

GDR

GoodRx Holdings, Inc.

Peer

-94.7%

-62.4%

-53.9%

-53.5%

-10.0%

+5.4%

BGM

BGM Group Ltd.

Peer

-90.8%

-38.2%

-66.0%

-64.4%

-12.5%

0.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

369.5

123.17

N/A

6.37

6.11

5.66

47.08

$711.9M

Profitability

Profit margins and return metrics

Profit Margin 4.31%

Operating Margin 0.32%

Gross Margin 95.36%

ROE 8.21%

ROA 4.93%

Growth

Revenue and earnings growth rates

Revenue Growth +33.4%

Earnings Growth N/A

Q/Q Revenue Growth +33.45%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.01

Low debt

Current Ratio

5.6

Strong

Quick Ratio

4.58

Excellent

Cash/Share

$0.57

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

95.3%

Op. Margin

0.3%

Net Margin

-4.6%

Total Assets

$0.2B

Liabilities

$0.0B

Equity

$0.1B

Debt/Equity

0.22x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

102%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07

$N/A

2026-03-12

$-0.02

-137.5% surprise

2025-11-07

$0.03

+250.0% surprise

2025-08-11

$N/A

-100.0% surprise

Healthcare Sector Comparison

Comparing GYRE against 226 companies in the Healthcare sector (19 bullish, 76 neutral, 131 bearish)

P/E Ratio

369.5

This Stock

45.29

Sector Avg

+715.9% (Expensive)

Return on Equity (ROE)

8.21%

This Stock

-40.43%

Sector Avg

-120.3% (Below Avg)

Profit Margin

4.31%

This Stock

-18.65%

Sector Avg

-123.1% (Weaker)

Debt to Equity

0.01

This Stock

4.61

Sector Avg

-99.9% (Less Debt)

Revenue Growth

33.4%

This Stock

97.21%

Sector Avg

-65.6% (Slower)

Current Ratio

5.6

This Stock

3.51

Sector Avg

+59.5% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
GYRE Gyre Therapeutics, Inc.	BEARISH	$711.9M	369.5	8.2%	4.3%	$7.39
ETON Eton Pharmaceuticals, Inc.	BEARISH	$720.17M	-	-18.2%	-5.8%	$26.39	Compare
BBNX Beta Bionics, Inc.	BEARISH	$702.63M	-	-47.5%	-87.9%	$15.96	Compare
GDRX GoodRx Holdings, Inc.	BEARISH	$739.96M	24.0	4.5%	3.8%	$2.16	Compare
BGM BGM Group Ltd.	BEARISH	$746.32M	-	-16.5%	-26.3%	$3.72	Compare

GYRE Gyre Therapeutics, Inc.

BEARISH

Mkt Cap

$712M

P/E

369.5

ROE

8.2%

Price

$7.39

Compare with GYRE

BBNX Beta Bionics, Inc.

Compare with GYRE

GDRX GoodRx Holdings, Inc.

Compare with GYRE

Compare with GYRE

Past News Coverage

Recent headlines mentioning GYRE from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

GYRE

GYRE Gyre Therapeutics, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Past News Coverage

Wait — Don't Miss Out!